A 49-year-old man with mantle cell lymphoma received 2.5 g/m 2 of cyclophosphamide and 900 mg/m 2 of etoposide followed by 10 g/kg/day of Filgrastim for PBPC mobilization. This was complicated by marked hyperleukocytosis and retinal hemorrhages. The patient's symptoms improved gradually following leukopheresis. To the best of our knowledge, this is the first report describing this complication in patients undergoing PBPC mobilization. Early recognition of symptoms is important in order to stop Filgrastim and initiate immediate leukapheresis. Keywords: Filgrastim; chemotherapy; PBPC mobilization; retinal hemorrhages; leukocytosis Mild to moderate bone pain is the most common side-effect associated with G-CSF use. Other rare reported adverse effects include splenomegaly secondary to extramedullary hematopoiesis, iritis, transient renal insufficiency, and exacerbation of underlying autoimmune diseases.
Mild to moderate bone pain is the most common side-effect associated with G-CSF use. Other rare reported adverse effects include splenomegaly secondary to extramedullary hematopoiesis, iritis, transient renal insufficiency, and exacerbation of underlying autoimmune diseases. [1] [2] [3] [4] [5] [6] Interestingly, complications resulting from leukocytosis are apparently rare. In this report, we describe a patient with non-Hodgkin's lymphoma (NHL) who developed dramatic hyperleukocytosis associated with impaired vision and retinal hemorrhages following chemotherapy and Filgrastim administration for peripheral blood progenitor cells (PBPC) mobilization.
Case report
A previously healthy 49-year-old man, presented with progressive abdominal discomfort. A computerized tomography (CT) scan of the abdomen showed a 10 × 9 cm mass arising from the ileal-cecal region with adjacent mesenteric and retroperitoneal lymph node involvement. The patient 49 × 10 9 /l. On the day of leukapheresis, he complained of a new paracentral visual blurred spot in the left eye, as well as persistent dizziness and generalized weakness.
On the following morning (day 16), ophthalmologic examination with indirect ophthalmoscopy and slit lamp biomicroscopy showed bilateral peripapillary and macular retinal hemorrhages as described in Figure 2a and b. The patient's best corrected vision was 20/400 right eye and 20/60 left eye; the anterior segment, vitreous, optic nerves, and intraocular pressures were normal. On the basis of the eye examination which suggested retinal leukostasis as well as a further increase in the WBC to 121 × 10 9 /l, a leukodepletion pheresis was performed on the same day (day 16). By the following day, the dizziness resolved and the generalized fatigue had improved. Subsequently, the vision improved gradually and ophthalmologic re-evaluation 3 weeks after leukapheresis showed significant improvement. Four weeks after PBPC collection, the patient received high-dose chemotherapy with BEAM (carmustine, etoposide, cytarabine, melphalan) followed by infusion of unmanipulated PBPC. transplant and did well for 10 months after transplant but then had recurrent disease.
Discussion
Hyperleukocytosis in patients with acute myeloid leukemias represent a serious complication because of the increased risk for the development of cerebral hemorrhages and respiratory failure. [7] [8] [9] Leukostasis is thought to be more commonly associated with myeloid than lymphoid leukemias because of the increased myeloblast's size and rigidity. 10 To the best of our knowledge, we believe that this is the first report of a patient with retinal hemorrhages and hyperleukocytosis secondary to chemotherapy and Filgrastim administration. The lack of severe thrombocytopenia or anemia at the time of onset of visual symptoms as well as the prompt response to leukapheresis, suggests that hyperleukocytosis was the dominant factor in the development of retinal hemorrhages in this patient. In addition, there was no recent history of ocular injury, coughing or vomiting.
Although retinal complications have not been previously reported in humans receiving hematopoietic growth factors, Keller and Smalling 11 described intracerebral hemorrhages in seven of 11 monkeys treated for 2-4 weeks with approximately 100 times the dose of recombinant G-CSF used in our patient. Although the WBC in our patient was greater than 100 × 10 9 /l at the time that leukapheresis was performed, he first reported symptoms when the WBC was only 25 × 10 9 /l. Therefore, other factors probably contributed to the development of retinal hemorrhages. For example, it has been suggested that patients with a rapid increase in leukocyte count may be at higher risk for leukostasis. 7, 8 It is also possible that the stimulatory effects of G-CSF on neutrophil metabolism may have produced an imbalance between oxygen supply and demand resulting in localized tissue hypoxia and disruption of the vascular endothelium.
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Whether G-CSF stimulation in the setting of a rapidly rising neutrophil count may have resulted in other adverse effects such as increased 'stickiness' or decreased deformability of the neutrophils is unknown. However, since the patient was treated with identical doses of Filgrastim after the PBPC transplant without complications, a direct toxic effect of Filgrastim is less likely.
Given the widespread use of Filgrastim and its excellent toxicity profile it is important to emphasize potential differences between the current patient and the majority of those that have been safely treated with Filgrastim. Firstly, many patients are 'protected' from the complications of hyperleukocytosis by the prior cumulative toxic effects of chemotherapy and/or radiation on the bone marrow. As our patient had received only three cycles of chemotherapy prior to PBPC mobilization, the bone marrow was probably relatively intact and obviously capable of intense myeloid proliferation. Secondly, the combination of highly myelosuppressive chemotherapy (as used in this patient) followed by Filgrastim stimulation is synergistic in stimulating myeloid progenitor cell proliferation. Indeed, after a brief nadir the WBC increased from 1.4 to 87 × 10 9 /l over 3 days, a rate of proliferation that is higher than all but the most aggressive neoplasms. Finally, the manufacturer's recommended dose of Filgrastim for PBPC mobilization (10 g/kg/day) is twice that used to promote neutrophil recovery after conventional therapy. While higher doses of Filgrastim may be necessary to mobilize PBPC in more heavily pretreated patients, this dose may be excessive in patients who have not had extensive therapy.
In conclusion, chemotherapy followed by daily Filgrastim administration is a common and effective method for mobilizing PBPC. While the more severe adverse effects associated with this strategy are nearly always due to the chemotherapy, the current case illustrates that clinicians should also be aware of complications resulting from the sometimes dramatic myeloid rebound that occurs in this setting. Indeed, vigilant monitoring of the WBC must persist after the period of neutropenia. Particularly as highdose therapy is integrated earlier into treatment in patients with intact bone marrow reserve, the potential for complications resulting from hyperleukocytosis such as respiratory or neurologic symptoms may also be expected to increase. Finally, early recognition of possible leukostasis is important in order to discontinue Filgrastim administration and to consider leukapheresis.
